Rare diseases
Investigational molecules
Locations
Study of tocilizumab compared to placebo in patients with chronic chondrocalcinosis who did not respond to standard treatments
FranceEvaluating Safety and Effectiveness of Combining Biologic Medications for Patients with Rheumatoid Arthritis and Psoriatic Arthritis ## Human: Give a detailed summary of a clinical trial for patients: 1.
SpainStudy on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren's Disease
FranceStudy on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis
FranceStudy on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment
FranceStudy on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases
AustriaStudy on the Safety and Effects of YTB323 and Drug Combination for Patients with Treatment-Resistant Generalized Myasthenia Gravis
FranceStudy on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis
AustriaStudy comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis
AustriaStudy on Rituximab, Tocilizumab, and Tofacitinib for Patients with Granulomatosis with Polyangiitis Not Responding to Standard Therapy
FranceStudy of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer
AustriaA study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
